Lupin appoints a Chief Corporate Development Officer, plus the pharma companies hiring Alzheimer's and HIV experts in this week's column.
Lupin, the Indian generics and branded pharmaceutical company, has made Theresa Stevens Chief Corporate Development Officer. She will be responsible for worldwide operations including global mergers and acquisitions and “specialty” business strategy. She moves from the same position at Aptalis Pharma, where she oversaw mergers and acquisitions, strategy and global business development. She previously held senior positions for nine years at Novartis.
As well as drug development, Lupin produces active pharmaceutical ingredients (APIs). The company bought last month Mexican drugmaker Grin as a “bridgehead” to generics and API growth in the region.
Copyright - Unless otherwise stated all contents of this web site are © 2017 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Welcome to in-PharmaTechnologist's monthly round up of who's been moving where in the small-molecule manufacturing world. The...
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...